WO2024052681A1 - Traitement du syndrome de rett - Google Patents
Traitement du syndrome de rett Download PDFInfo
- Publication number
- WO2024052681A1 WO2024052681A1 PCT/GB2023/052315 GB2023052315W WO2024052681A1 WO 2024052681 A1 WO2024052681 A1 WO 2024052681A1 GB 2023052315 W GB2023052315 W GB 2023052315W WO 2024052681 A1 WO2024052681 A1 WO 2024052681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- editing
- nucleic acid
- sequence
- base
- cas9
- Prior art date
Links
- 208000006289 Rett Syndrome Diseases 0.000 title claims abstract description 33
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 238000012217 deletion Methods 0.000 claims abstract description 35
- 230000037430 deletion Effects 0.000 claims abstract description 35
- 101150083522 MECP2 gene Proteins 0.000 claims abstract description 32
- 108020004705 Codon Proteins 0.000 claims abstract description 29
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 80
- 150000007523 nucleic acids Chemical class 0.000 claims description 72
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 229930024421 Adenine Natural products 0.000 claims description 27
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 27
- 229960000643 adenine Drugs 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 10
- 230000037433 frameshift Effects 0.000 claims description 7
- -1 phagemid Substances 0.000 claims description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 239000013607 AAV vector Substances 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 108091007054 readthrough proteins Proteins 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 230000012863 translational readthrough Effects 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 84
- 230000035772 mutation Effects 0.000 abstract description 61
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 abstract description 33
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 abstract description 33
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000004075 alteration Effects 0.000 abstract description 4
- 108091033409 CRISPR Proteins 0.000 description 114
- 235000018102 proteins Nutrition 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 63
- 108020005004 Guide RNA Proteins 0.000 description 53
- 102000053602 DNA Human genes 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 37
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 102000055025 Adenosine deaminases Human genes 0.000 description 31
- 108020001507 fusion proteins Proteins 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 28
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 238000010354 CRISPR gene editing Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000010362 genome editing Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 101710163270 Nuclease Proteins 0.000 description 14
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 12
- 229920002401 polyacrylamide Polymers 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000006481 deamination reaction Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108091079001 CRISPR RNA Proteins 0.000 description 10
- 230000009615 deamination Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 8
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108091028113 Trans-activating crRNA Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 108700040115 Adenosine deaminases Proteins 0.000 description 7
- 238000010357 RNA editing Methods 0.000 description 7
- 230000026279 RNA modification Effects 0.000 description 7
- 241000193996 Streptococcus pyogenes Species 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- 238000010442 DNA editing Methods 0.000 description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 6
- 101710096438 DNA-binding protein Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000003007 single stranded DNA break Effects 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000000981 bystander Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000005782 double-strand break Effects 0.000 description 5
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012165 high-throughput sequencing Methods 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 102000008682 Argonaute Proteins Human genes 0.000 description 4
- 108010088141 Argonaute Proteins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 230000007018 DNA scission Effects 0.000 description 4
- 229930010555 Inosine Natural products 0.000 description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 229960003786 inosine Drugs 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000049101 human MECP2 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000017730 intein-mediated protein splicing Effects 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000016434 protein splicing Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 101150069031 CSN2 gene Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100033636 Histone H3.2 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010015268 Integration Host Factors Proteins 0.000 description 2
- 101001033765 Mus musculus Methyl-CpG-binding protein 2 Proteins 0.000 description 2
- 241000169176 Natronobacterium gregoryi Species 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008970 bacterial immunity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 101150055601 cops2 gene Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002873 global sequence alignment Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004777 loss-of-function mutation Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000616876 Belliella baltica Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000010804 Caulobacter vibrioides Species 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108060003760 HNH nuclease Proteins 0.000 description 1
- 102000029812 HNH nuclease Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 208000024889 MECP2 duplication syndrome Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101150065592 NME2 gene Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 240000000968 Parkia biglobosa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000033876 Proximal Xq28 duplication syndrome Diseases 0.000 description 1
- 241000577544 Psychroflexus torquis Species 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241001148570 Rhodothermus marinus Species 0.000 description 1
- 102100036007 Ribonuclease 3 Human genes 0.000 description 1
- 101710192197 Ribonuclease 3 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000863432 Shewanella putrefaciens Species 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241001606419 Spiroplasma syrphidicola Species 0.000 description 1
- 241000203029 Spiroplasma taiwanense Species 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241001313536 Thermothelomyces thermophila Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Definitions
- compositions for use in the treatment of a class of Rett syndrome mutations namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene.
- This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wildtype version of the MeCP2 protein.
- RTT Rett Syndrome
- MECP2 Rett Syndrome
- Loss of MeCP2 function has the most profound effect in the nervous system, with minimal phenotypic consequences in other tissues ((Ross et al. 2016).
- the MECP2 gene is frequently screened for mutations in clinical cases of developmental delay. This has defined many amino acid changes as RTT-causing or as relatively benign or neutral variants that do not cause RTT (Krishnaraj et al 2017, and Karczewski, et al. 2020).
- RTT-like symptoms in Mecp2-null mice can be rescued by restoring MeCP2 expression, suggesting that the disorder may be curable.
- Most RTT-causing mutations disrupt two domains, which are required for normal MeCP2 function; however, there are mutations, which affect the region C-terminal to these domains. These mutations cause RTT by dramatically reducing MeCP2 protein levels (Guy et al. 2018).
- mice lacking this C-terminal region, which express normal levels of MeCP2 protein do not have RTT-like symptoms, indicating that this region is dispensable for normal MeCP2 function.
- a heterogeneous group of frameshifting C-terminal deletions account for -10% of RTT-causing mutations. They occur within a deletion-prone region of MECP2 from approximately c.1110-1210 (numbered based on e2 isoform) (Bebbington et al, 2010). The inventors have found that the outcome of deletions in this region is dependent on the resulting reading frame. In-frame deletions which remove a portion of the DNA in this region, but still maintain the WT reading frame are present in large-scale sequencing databases, which exclude individuals with severe paediatric disease, indicating that they are non-pathogenic neutral variants (see Figure 3).
- the present disclosure is based on an initial hypothesis by the inventors that for RTT subjects, with a deletion in exon 4 of MECP2, which result in a shift to frame(n+2), it is the presence of the two prolines before a stop codon which disrupt translational termination, resulting in loss of MeCP2 protein and mRNA in a process similar to nonsense-mediated decay. Based on this, the inventors predicted that changing the stop codon following the two prolines to one coding an amino acid, leading to further translation to the next stop codon, may prevent the loss of MeCP2 protein that is pathogenic in this class of mutations.
- the present disclosure provides a base editing construct for use in a method of treating Rett Syndrome in a subject, wherein the subject comprises a mutant MECP2 gene comprising a C-terminal deletion which results in a translation frameshift (n+2) and expression of a truncated MECP2 gene ending -Pro-Pro-Stop, wherein the construct is capable of editing the stop codon in order to permit translational read-through.
- the present inventors observed, from sequence information obtained from subjects with Rett syndrome, that certain C terminal deletions, approximately c.111Q- 1210 (numbered based on e2 isoform), result in a +2 frameshift and the generation of a truncated MECP2 protein, which ends -Pro-Pro-Stop (PPX).
- the nucleic acid sequence encoding this is CCCCCCTGA.
- the present invention describes editing the adenine base in the TGA stop codon to another base, such as guanine, or optionally cytosine, or thymine to result in a codon other than a stop codon.
- TGG tryptophan
- one suitable base editing method involves using a singleguide RNA (sgRNA) to target an adenine base editor (ABE) to the target adenine of the TGA stop codon.
- sgRNA singleguide RNA
- ABE adenine base editor
- the inventors have observed that the guide sequence is present in (almost) all CTD RTT-alleles. Thus, the therapy should be applicable to this whole class of mutations.
- the edited gene will not produce wild-type protein, but will encode a truncation that in the work exemplified herein retains the functions of native MeCP2.
- RTT RTT-reduction tumor necrosis tethelial growth factor
- RNA editing approaches or use of read-through compounds for nonsense mutations A limitation of these strategies is that they will require repeat dosing in order to maintain levels of corrected mRNA.
- a base editing technique such as using an ABE on the other hand, will result in permanent correction of the gene, and prove therapeutic once a sufficient number of cells have been modified.
- gene editing would simply revert the mutation back to WT, which in theory could be done using homology-directed repair (HDR) of Cas9-induced double strand breaks (DSBs), by supplying an exogenous DNA repair template.
- HDR homology-directed repair
- DSBs Cas9-induced double strand breaks
- the strategy would be highly useful for ex vivo approaches where the edited cells can be expanded in culture first before returning them to the body, or if a population of dividing cells in which there is a selective advantage for edited cells over unedited cells is being targeted.
- this approach is unsuitable for RTT because the target population is post-mitotic neurons, in which HDR levels are low and there is no means of selection.
- the present strategy avoids this problem by relying solely on the single step of editing the endogenous sequence, rather than editing/inserting a new sequence.
- DSBs introduced as part of the HDR repair process carry a higher risk of undesirable mutagenic events than base editing.
- sqRNA (or a set of sqRNAs) can be used for all CTD mutations
- RTT C-terminal deletions are a heterogeneous set of mutations, with many individual deletions seen only once or a small number of times. This strategy targets the problematic sequence that is thought to be present in the whole class, thus making the therapy applicable to around 10% of RTT patients, comparable with the most commonly detected missense mutations.
- the two critical functional domains, the MBD (methylated DNA binding domain; a. a.78-162) and the NID (NCoR1/2 interaction domain; a. a.301-309) are unaffected by CTD mutations.
- ExAC and GnomAD data shows that the C-terminal deletion-prone region is very tolerant of missense mutations and in-frame deletions.
- Base editors may be fusions of a Cas (“CRISPR-associated”) domain and a nucleobase (or “base”) modification domain (e.g., a natural or evolved deaminase, such as an adenosine deaminase domain).
- base editors may also include proteins or domains that affect cellular DNA repair processes to increase the efficiency and/or stability of the resulting single-nucleotide change.
- Base editors generally contain a catalytically impaired Cas9 domain fused to a nucleobase modification domain.
- the Cas9 domain directs the nucleobase modification domain to directly convert one base to another at a guide RNA-programmed target site.
- Two classes of base editors have been developed to date: Cytosine base editors (CBEs), which convert C*G to T A, and adenine base editors (ABEs), which convert A T to G*C.
- CBEs Cytosine base editors
- ABEs adenine base editors
- ABEs are especially useful for the study and correction of pathogenic alleles, as nearly half of pathogenic point mutations in principle can be corrected by converting an A T base pair to a G*C base pair.
- Many of the ABEs reported to date include a single polypeptide chain containing a heterodimer of a wild-type E. coli TadA monomer (ecTadA, or TadA) that plays a structural role during base editing and a laboratory-evolved E.
- TadA* coli TadA monomer TadA7.10 (also referred to herein as “TadA*”) that catalyzes deoxyadenosine deamination, and a Cas9 (D10A) nickase.
- Wild type E. coli TadA acts as a homodimer to deaminate an adenosine located in a tRNA anticodon loop, generating inosine (I).
- I inosine
- early ABE variants required a heterodimeric TadA containing an N-terminal wild-type TadA monomer for maximal activity, later work showed that later ABE variants have comparable activity with and without the wildtype TadA monomer.
- Guide RNA-dependent off-target base editing has been reduced through strategies including installation of mutations that increase DNA specificity into the Cas9 component of base editors, adding 5' guanosine nucleotides to the sgRNA, or delivery of the base editor as a ribonucleoprotein complex (RNP).
- Guide RNA-independent off-target editing can arise from binding of the deaminase domain of a base editor to C or A bases in a Cas9- independent manner.
- the ABEs for use in accordance with the present disclosure may comprise fusion proteins comprising a nucleic acid DNA binding protein (or napDNAbp) domain and an adenosine deaminase domain.
- the napDNAbp domain may comprise a Cas9 protein, or a variant thereof, e.g., a Cas9 nickase or a Cas9 nickase with altered PAM specificity.
- the adenosine deaminase domain may comprise one or more adenosine deaminases.
- the adenosine deaminase domain comprises a dimer of a first and second adenosine deaminase.
- the dimer may be a heterodimer, comprising a first adenosine deaminase that is different from a second adenosine deaminase.
- the first adenosine deaminase may be positioned N-terminal to the second adenosine deaminase.
- the one or more adenosine deaminases are connected by a linker (e.g., a peptide linker).
- Suitable ABEs may be capable of preserving DNA editing efficiency, and in some embodiments demonstrate improved DNA editing efficiencies, relative to existing adenine base editors, such as ABE7.10 - see, for example WO2020214842, the entire contents of which are hereby incorporated.
- WO2020214842 describes ABEs, which exhibit reduced off- target editing effects while retaining high on-target editing efficiencies, as well as more recent ABEs described in Richter (2020), Walton (2020), Gaudelli (2020) and Chen (2022).
- Suitable ABEs may be compatible with a variety of Cas homologs, including small-sized, circularly permuted, and evolved Cas homologs.
- compositions comprising an ABE, such as an ABE with reduced off-target effects, such as reduced RNA editing effects e.g., fusion proteins comprising an nCas9 domain and an adenosine deaminase domain (e.g., a heterodimer of a first and second adenosine deaminase), and one or more guide RNAs, e.g., a single-guide RNA (“sgRNA”).
- ABE such as an ABE with reduced off-target effects
- reduced RNA editing effects e.g., fusion proteins comprising an nCas9 domain and an adenosine deaminase domain (e.g., a heterodimer of a first and second adenosine deaminase)
- guide RNAs e.g., a single-guide RNA (“sgRNA”).
- the present disclosure further teaches nucleic acid molecules encoding and/or expressing the adenine base editors as described herein, and the adenosine deaminase domains thereof, as well as expression vectors or constructs for expressing the adenine base editors described herein and a gRNA (e.g. sgRNA), cells (such as host cells) comprising said nucleic acid molecules and expression vectors, and one or more gRNAs (e.g. sgRNA), and compositions for delivering and/or administering nucleic acid molecules for expression in cells of RTT subjects with the described deletion in exon 4 of MECP2, which result in a shift to frame(n+2).
- the nucleic acid sequences may be codon-optimized for expression in human cells, using techniques well-known to those skilled in the art.
- the present specification further teaches complexes comprising the adenine base editors described herein and a gRNA (e.g. sgRNA) bound to the Cas9 domain of the fusion protein.
- the guide RNA may be 50-150, such as 90-100 or 80 -110 nucleotides in length and comprise a sequence of at least 10, at least 15, or at least 20 or 25 contiguous nucleotides that is complementary to a target nucleotide sequence. Typically, the sequence is no longer than 30 or 35 nucleotides in length.
- kits for expressing and/or transducing cells such as host cells
- an expression construct encoding the fusion protein and gRNA.
- the disclosure further teaches host cells stably or transiently expressing the fusion protein and gRNA (e.g. sgRNA), or a complex thereof.
- the present teaching may further include first screening RTT subjects for such C-terminal frameshift (n+2) deletion mutations, in order to identify subjects suitable for treatment in accordance with the present invention.
- suitable screening techniques including nucleic acid sequencing of a subject’s MDCP2 gene sequence, PCR and other amplification techniques, hybridisation techniques using suitable probes etc.
- Methods are also taught for editing a mutant MECP2 gene, as described herein, e.g., a single nucleobase within the mutant MECP2 gene, with an adenine base editor described herein.
- Such methods involve transducing (e.g., via transfection) cells with a plurality of complexes each comprising a fusion protein (e.g., a fusion protein comprising a Cas9 nickase (nCas9) domain and an adenosine deaminase domain) and a gRNA (e.g. sgRNA) molecule.
- a fusion protein e.g., a fusion protein comprising a Cas9 nickase (nCas9) domain and an adenosine deaminase domain
- gRNA e.g. sgRNA
- the methods involve the transfection of one or more nucleic acid constructs (e.g., plasmids, phagemids, or viral vectors) that each (or together) encode the components of a complex of fusion protein and gRNA (e.g. sgRNA) molecule.
- the methods disclosed herein may involve the introduction into cells of a complex comprising a fusion protein and gRNA (e.g. sgRNA) molecule that has been expressed and cloned outside of these cells.
- delivery to neurons in the brain using a viral vector, such as an adeno-associated virus (AAV) vector (e.g. AAV9), is most appropriate.
- AAV adeno-associated virus
- nucleic acid encoding suitable base editors may be too big, to fit into and be expressed by a single viral vector.
- the base editor may be encoded in two or more separate parts, which can be reconstituted into the full-length molecule by protein splicing. This is facilitated by the addition of split intein sequences adjacent to the sequences to be joined (see Chen (2020, for example).
- methods of treating RTT due to a mutant MECP2 gene as described herein, using the disclosed base editors are provided.
- the methods described herein may comprise treating a subject having or at risk of developing RTT, comprising administering (in an effective amount) to the subject a fusion protein as described herein, a complex as described herein, a polynucleotide as described herein, a vector as described herein, or a pharmaceutical composition as described herein.
- adenosine deaminase domain refers to a domain within a fusion protein comprising one or more adenosine deaminases.
- an adenosine deaminase domain may comprise a heterodimer of a first adenosine deaminase and a second deaminase domain, connected by a linker, or a single engineered adenosine deaminase domain.
- Base editing refers to genome editing technology that involves the conversion of a specific nucleic acid base into another at a targeted genomic locus. In certain embodiments, this can be achieved without requiring double- stranded DNA breaks (DSB), or single stranded breaks (i.e. nicking).
- DSB double- stranded DNA breaks
- Other genome editing techniques including CRISPR- based systems, begin with the introduction of a DSB at a locus of interest. Subsequently, cellular DNA repair enzymes mend the break, commonly resulting in random insertions or deletions (indels) of bases at the site of the DSB.
- Base editing construct refers to a system comprising a suitable enzyme and optionally a nucleic acid capable of binding a target nucleic acid, for use in base editing.
- Adenine base editor (or “ABE”). This type of editor converts an A:T Watson- Crick nucleobase pair to a G:C Watson-Crick nucleobase pair. Because the corresponding Watson- Crick paired bases are also interchanged as a result of the conversion, this category of base editor may also be referred to as a thymine base editor (or “TBE”).
- base editor refers to an agent comprising a polypeptide that is capable of making a modification to a base (e.g ., A, T, C, G, or II) within a nucleic acid sequence (e.g., DNA or RNA).
- the base editor is capable of deaminating a base within a nucleic acid such as a base within a DNA molecule.
- the base editor is capable of deaminating an adenine (A) in DNA.
- Such base editors may include a nucleic acid programmable DNA binding protein (napDNAbp) fused to an adenosine deaminase.
- napDNAbp nucleic acid programmable DNA binding protein
- the base editor comprises a nuclease-inactive Cas9 (dCas9) fused to a deaminase which binds a nucleic acid in a guide RNA-programmed manner via the formation of an R-loop, but does not cleave the nucleic acid.
- the dCas9 domain of the fusion protein may include a D10A and a H840A mutation (which renders Cas9 capable of cleaving only one strand of a nucleic acid duplex), as described in WO 2017/070632 and is incorporated herein by reference in its entirety.
- the DNA cleavage domain of S. pyogenes Cas9 includes two subdomains, the HNH nuclease subdomain and the RuvCI subdomain.
- the HNH subdomain cleaves the strand complementary to the gRNA (the “targeted strand”, or the strand in which editing or deamination occurs), whereas the RuvCI subdomain cleaves the non-complementary strand containing the PAM sequence (the “non-edited strand”).
- the RuvCI mutant D10A generates a nick in the targeted strand, while the HNH mutant H840A generates a nick on the non-edited strand (see Jinek et al, Science , 337:816-821 (2012); Qi et al, Cell. 28; 152(5): 1173-83 (2013)).
- base editor encompasses the CRISPR-mediated fusion proteins utilized in the multiplexed base editing methods described herein as well as any base editor known or described in the art at the time of this filing or developed in the future.
- base editing precision chemistry on the genome and transcriptome of living cells, Nat. Rev. Genet. 2018;19(12):770-788; as well as U.S. Patent Publication No. 2018/0073012; U.S. Patent Publication No. 2017/0121693; International Publication No. WO2017/070633; U.S. Patent Publication No. 2015/0166980; International Publication No. WO 2017/070633; International Publication No.
- Cas9 or “Cas9 nuclease” or“ Cas9 domain” refers to a CRISPR-associated protein 9, or variant thereof, and embraces any naturally occurring Cas9 from any organism, any naturally-occurring Cas9 equivalent or fragment thereof, any Cas9 homolog, ortholog, or paralog from any organism, and any variant of a Cas9, naturally-occurring or engineered.
- the term Cas9 thus extends to compact Cas9 variants, such as Nme2 variants, which have been developed (see Erdaki et al, 2019)
- Cas9 is not meant to be particularly limiting and may be referred to as a “Cas9 or variant thereof.”
- Exemplary Cas9 proteins are described herein and also described in the art. The present disclosure is unlimited with regard to the particular Cas9 that is employed in the CRISPR-mediated fusion proteins utilized in the disclosure.
- proteins comprising Cas9 or fragments thereof are referred to as “Cas9 variants.”
- a Cas9 variant shares homology to Cas9, or a fragment thereof.
- Cas9 variants include functional fragments of Cas9.
- a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild type Cas9.
- the Cas9 variant may have 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 21 , 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to a wild type Cas9.
- the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9.
- a fragment of Cas9 e.g., a gRNA binding domain or a DNA-cleavage domain
- the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9.
- dCas9 refers to a nuclease-inactive Cas9 or nuclease-dead Cas9, or a variant thereof, and embraces any naturally occurring dCas9 from any organism, any naturally-occurring dCas9 equivalent or functional fragment thereof, any dCas9 homolog, ortholog, or paralog from any organism, and any variant of a dCas9, naturally- occurring or engineered.
- dCas9 is not meant to be particularly limiting and may be referred to as a“dCas9 or variant thereof.”
- Exemplary dCas9 proteins and method for making dCas9 proteins are further described herein and/or are described in the art and are incorporated herein by reference.
- Any suitable mutation which inactivates both Cas9 endonucleases such as D10A and H840A mutations in the wild-type S. pyogenes Cas9 amino acid sequence, or D10A and N580A mutations in the wild-type S. aureus Cas9 amino acid sequence, may be used to form the dCas9.
- nCas9 or “Cas9 nickase” refers to a Cas9 or a variant thereof, which cleaves or nicks only one of the strands of a target cut site thereby introducing a nick in a double strand DNA molecule rather than creating a double strand break.
- This can be achieved by introducing appropriate mutations in a wild-type Cas9, which inactivates one of the two endonuclease activities of the Cas9.
- Any suitable mutation which inactivates one Cas9 endonuclease activity but leaves the other intact is contemplated, such as one of D10A or H840A mutations in the wild-type S.
- pyogenes Cas9 amino acid sequence, ora D10A mutation in the wild-type S. aureus Cas9 amino acid sequence may be used to form the nCas9.
- CRISPR is a family of DNA sequences (i.e. , CRISPR clusters) in bacteria and archaea that represent snippets of prior infections by a virus that have invaded the prokaryote.
- the snippets of DNA are used by the prokaryotic cell to detect and destroy DNA from subsequent attacks by similar viruses and effectively constitute, along with an array of CRISPR-associated proteins (including Cas9 and homologs thereof) and CRISPR-associated RNA, a prokaryotic immune defence system.
- CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA).
- tracrRNA trans-encoded small RNA
- me endogenous ribonuclease 3
- Cas9 protein a trans-encoded small RNA
- the tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA.
- Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular nucleic acid target complementary to the RNA. Specifically, the target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically.
- RNA-binding and cleavage typically requires protein and both RNAs.
- single guide RNAs (“sgRNA”, or simply “gRNA”) may be engineered so as to incorporate embodiments of both the crRNA and tracrRNA into a single RNA species — the guide RNA.
- sgRNA single guide RNAs
- Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self, versus non-self.
- CRISPR biology as well as Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti J. J., et al, Proc. Natl. Acad. Sci. U.S.A.
- Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference.
- Other relevant teachings, to which the skilled reader is directed and the entire contents of which are hereby incorporated by way of reference include Kleinstiver (2016, Slaymaker (2015) and Vakulskas (2018).
- deaminase or “deaminase domain” refers to a protein or enzyme that catalyzes a deamination reaction.
- the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenine or adenosine.
- the adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA) to inosine (and thus the conversion of adenine base to hypoxanthine base).
- the deaminases provided herein may be from any organism, such as a bacterium.
- the deaminase or deaminase domain is a variant of a naturally-occurring deaminase from an organism. In some embodiments, the deaminase or deaminase domain does not occur in nature. For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occurring deaminase.
- Adenosine deaminases e.g. engineered adenosine deaminases, evolved adenosine deaminases
- Adenosine deaminases may be enzymes that convert adenosine (A) to inosine (I) in DNA or RNA.
- Such adenosine deaminase can lead to an A:T to G:C base pair conversion.
- the deaminase is a variant of a naturally-occurring deaminase from an organism. In some embodiments, the deaminase does not occur in nature.
- the deaminase is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occurring deaminase.
- the adenosine deaminase is derived from a bacterium, such as, E.coli, S. aureus, S. typhi, S. putrefaciens, H. influenzae, or C. crescentus.
- the adenosine deaminase is a TadA deaminase.
- the TadA deaminase is an E. coli TadA deaminase (ecTadA).
- the TadA deaminase is a truncated E. coli Tad deaminase.
- the truncated ecTadA may be missing one or more N-terminal amino acids relative to a full-length ecTadA.
- the truncated ecTadA may be missing 1 , 2, 3, 4, 5 ,6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the truncated ecTadA may be missing 1 , 2, 3, 4, 5 ,6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 6, 17, 18, 19, or 20 C-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the ecTadA deaminase does not comprise an N-terminal methionine. Reference is made to U.S. Patent Publication No. 2018/0073012, the entire contents of which is incorporated herein by reference.
- DNA binding protein or“DNA binding protein domain” refers to any protein that localizes to and binds a specific target DNA nucleotide sequence (e.g. a gene locus of a genome).
- This term embraces RNA-programmable proteins, which associate (e.g. form a complex) with one or more nucleic acid molecules (i.e., which includes, for example, guide RNA in the case of Cas systems) that direct or otherwise program the protein to localize to a specific target nucleotide sequence (e.g., DNA sequence) that is complementary to the one or more nucleic acid molecules (or a portion or region thereof) associated with the protein.
- RNA-programmable proteins are CRISPR-Cas9 proteins, as well as Cas9 equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g. engineered or modified), and may include a Cas9 equivalent from any type of CRISPR system (e.g.
- Type II, V, VI including Casl2a (a type-V CRISPR-Cas system) (formerly known as Cpfl), C2cl (a type V CRISPR-Cas system), C2c2 (a type VI CRISPR-Cas system), C2c3 (a type V CRISPR-Cas system), a GeoCas9, a CjCas9, a Casl2b, a Casl2g, a Casl2h, a Casl2i, a Casl3b, a Casl3c, a Casl3d, a Casl4, a Csn2, an xCas9, an SpCas9-NG, a Cas9-KKH, a circularly permuted Cas9, an Argonaute (Ago), a SmacCas9, or a Spy- macCas9.
- Casl2a a type-V CRISPR-Ca
- C2c2 is a singlecomponent programmable RNA-guided RNA-targeting CRISPR effector,” Science 2016; 353(6299), the contents of which are incorporated herein by reference.
- DNA editing efficiency refers to the number or proportion of intended base pairs that are edited. For example, if a base editor edits 10% of the base pairs that it is intended to target (e.g., within a cell or within a population of cells), then the base editor can be described as being 10% efficient.
- Some aspects of editing efficiency embrace the modification (e.g. deamination) of a specific nucleotide within DNA, without generating a large number or percentage of insertions or deletions (i.e. , indels). It is generally accepted that editing while generating less than 5% indels (as measured over total target nucleotide substrates) is high editing efficiency. The generation of more than 20% indels is generally accepted as poor or low editing efficiency. Indel formation may be measured by techniques known in the art, including high-throughput screening of sequencing reads.
- off-target editing frequency refers to the number or proportion of unintended base pairs, e.g. DNA base pairs that are edited.
- On-target and off-target editing frequencies may be measured by the methods and assays described herein, further in view of techniques known in the art, including high-throughput sequencing reads.
- high-throughput sequencing involves the hybridization of nucleic acid primers (e.g., DNA primers) with complementarity to nucleic acid (e.g., DNA) regions just upstream or downstream of the target sequence or off-target sequence of interest.
- nucleic acid primers with sufficient complementarity to regions upstream or downstream of the target sequence and Cas9-independent off-target sequences of interest may be designed using techniques known in the art, such as the Phusionll PCR kit (Fife Technologies), Phusion HS II kit (Fife Technologies), and Illumina MiSeq kit. Since many of the Cas9-dependent off-target sites have high sequence identity to the target site of interest, nucleic acid primers with sufficient complementarity to regions upstream or downstream of the Cas9-dependent off-target site may likewise be designed using techniques and kits known in the art. These kits make use of polymerase chain reaction (PCR) amplification, which produces amplicons as intermediate products.
- the target and off- target sequences may comprise genomic loci that further comprise protospacers and PAMs.
- amplicons may refer to nucleic acid molecules that constitute the aggregates of genomic loci, protospacers and PAMs.
- High-throughput sequencing techniques used herein may further include Sanger sequencing and/or whole genome sequencing (WGS).
- RNA editing activity refers to the introduction of modifications (e.g. deaminations) to nucleotides within cellular RNA, e.g. messenger RNA (mRNA).
- modifications e.g. deaminations
- mRNA messenger RNA
- An important goal of DNA base editing efficiency is the modification (e.g. deamination) of a specific nucleotide within DNA, without introducing modifications of similar nucleotides within RNA.
- RNA editing effects are “low” or “reduced” when a detected mutation is introduced into RNA molecules at a frequency of 0.3% or less.
- the ABEmax base editor introduces edits into RNA at a frequency of about 0.50%.
- RNA editing effects are “low” or “reduced” when a mutation is detected at a magnitude that is less than about 70,000 edits within an analyzed mRNA transcriptome.
- the number of RNA edits may be measured by techniques known in the art, including high-throughput screening of sequencing reads and RNA-seq.
- the effects of RNA editing on the function of a protein translated from the edited mRNA transcript may be predicted by use of the SIFT (“Sorting Intolerant from Tolerant”) algorithm, which bases predictions on sequence homology and the physical properties of amino acids.
- on-target editing refers to the introduction of intended modifications (e.g., deaminations) to nucleotides (e.g., adenine) in a target sequence, such as using the base editors described herein.
- off-target DNA editing refers to the introduction of unintended modifications (e.g. deaminations) to nucleotides (e.g. adenine) in a sequence outside the canonical base editor binding window (i.e., from one protospacer position to another, typically 2 to 8 nucleotides long).
- Off-target DNA editing can result from weak or non-specific binding of the gRNA sequence to the target sequence. Exemplary teachings, the entire contents of which are hereby incorporated by way of reference, describing ways of reducing off-target editing may be found in Grunwald (2019) and Rees (2019).
- an effective amount refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response.
- an effective amount of a composition may refer to the amount of the composition that is sufficient to edit a target site of a nucleotide sequence, e.g. a genome.
- an effective amount of a composition provided herein e.g. of a composition comprising a nuclease-inactive Cas9 domain, a deaminase domain, a gRNA and optionally a growth factor and anti-apoptotic factor, may refer to the amount of the composition that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein.
- an effective amount of a composition provided herein may refer to the amount of the composition sufficient to induce editing having the following characteristics: > 50% product purity, ⁇ 5% indels, and an editing window of 2-8 nucleotides.
- an agent e.g. a composition or a fusion protein- gRNA complex
- the effective amount of an agent may vary depending on various factors as, for example, on the desired biological response, e.g. on the specific allele, genome, or target site to be edited, on the cell or tissue being targeted, and on the agent being used.
- evolved base editor or “evolved base editor variant” refers to a base editor formed as a result of mutagenizing a reference or starting-point base editor.
- the term refers to embodiments in which the nucleobase modification domain is evolved or a separate domain is evolved.
- Mutagenizing a reference or starting-point base editor may comprise mutagenizing an adenosine deaminase.
- Amino acid sequence variations may include one or more mutated residues within the amino acid sequence of a reference base editor, e.g., as a result of a change in the nucleotide sequence encoding the base editor that results in a change in the codon at any particular position in the coding sequence, the deletion of one or more amino acids (e.g., a truncated protein), the insertion of one or more amino acids, or any combination of the foregoing.
- the evolved base editor may include variants in one or more components or domains of the base editor (e.g., variants introduced into one or more adenosine deaminases).
- fusion protein refers to a hybrid polypeptide, which comprises protein domains from at least two proteins.
- One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C- terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively.
- a protein may comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein.
- any of the proteins provided herein may be produced by any method known in the art.
- the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker.
- Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.
- a suitable host cell refers to a cell that can host, replicate, and transfer a nucleic acid or vector as discussed herein.
- a suitable host cell is a cell that may be infected by the viral vector, can replicate it, and can package it into viral particles that can infect fresh host cells.
- a cell can host a viral vector if it supports expression of genes of viral vector, replication of the viral genome, and/or the generation of viral particles.
- One criterion to determine whether a cell is a suitable host cell for a given viral vector is to determine whether the cell can support the viral life cycle of a wildtype viral genome that the viral vector is derived from.
- a suitable host cell would be any cell that can support the wild-type M13 phage life cycle.
- Suitable host cells for viral vectors useful in continuous evolution processes are well known to those of skill in the art, and the disclosure is not limited in this respect.
- the viral vector is a phage and the host cell is a bacterial cell.
- the host cell is an E. coli cell. Suitable
- E. coli host strains will be apparent to those of skill in the art, and include, but are not limited to, New England Biolabs (NEB) Turbo, ToplOF’, DH12S, ER2738, ER2267, and XLI-Blue MRF’. These strain names are art recognized and the genotype of these strains has been well characterized.
- fresh as used herein interchangeably with the terms “non- infected” or “uninfected” in the context of host cells, refers to a host cell that has not been infected by a viral vector comprising a gene of interest as used in a continuous evolution process provided herein. A fresh host cell can, however, have been infected by a viral vector unrelated to the vector to be evolved or by a vector of the same or a similar type but not carrying the gene of interest.
- the host cell is a prokaryotic cell, for example, a bacterial cell. In some embodiments, the host cell is an E. coli cell. In some embodiments, the host cell is a eukaryotic cell, for example, a yeast cell, an insect cell, or a mammalian cell.
- the type of host cell will, of course, depend on the viral vector employed, and suitable host cell/vector combinations will be readily apparent to those of skill in the art.
- the host cell may be a neurological cell, such as a neuron, e.g. an excitatory or inhibitory neuron, or glial cells such as astrocytes and microglia.
- a neuron e.g. an excitatory or inhibitory neuron
- glial cells such as astrocytes and microglia.
- linker refers to a chemical group or a molecule linking two molecules or domains, e.g. dCas9 and a deaminase. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other domains and connected to each one via a covalent bond, thus connecting the two.
- the linker is an amino acid or a plurality of amino acids (e.g. a peptide or protein).
- the linker is an organic molecule, group, polymer, or chemical domain. Chemical groups include, but are not limited to, disulfide, hydrazone, and azide domains.
- the linker is 5- 100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.
- the linker is an XTEN linker.
- the term “low toxicity” refers to the maintenance of a viability above 60% in a population of cells following application of a base editing method or administration of a composition disclosed herein.
- the term may also refer to prevention of apoptosis (cell death) in a population of cells of more than 40%.
- a genome editing method that leads to less than 30% (e.g. 25%, 20%, 15%, 10%, or 5%) cell death exhibits low toxicity.
- Cell toxicity may be assessed by an appropriate staining assay, e.g. Annexin V and propidium iodide staining assays, and subsequent flow cytometry (e.g. FACS).
- mutation refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue; a deletion or insertion of one or more residues within a sequence; or a substitution of a residue within a sequence of a genome in a subject to be corrected. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).
- Mutations can include a variety of categories, such as single base polymorphisms, microduplication regions, indel, and inversions, and is not meant to be limiting in any way. Mutations can include “loss-of- function” mutations which is a result of a mutation that reduces or abolishes a protein activity. Most loss- of-function mutations are recessive, because in a heterozygote the second chromosome copy carries an unmutated version of the gene coding for a fully functional protein whose presence compensates for the effect of the mutation. There are some exceptions where a loss-of- function mutation is dominant, one example being haploinsufficiency, where the organism is unable to tolerate the approximately 50% reduction in protein activity suffered by the heterozygote. This is the explanation for a few genetic diseases in humans, including Marfan syndrome, which results from a mutation in the gene for the connective tissue protein called fibrillin.
- T ranslational read-though in the context of the present disclosure, is the consequence editing the third base of the TGA stop codon, such that the resulting codon no longer encodes a stop codon and translation can continue until the next stop codon occurs.
- nucleic acid molecules or polypeptides e.g. deaminases
- nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and/or as found in nature (e.g. an amino acid sequence not found in nature).
- nucleic acid refers to RNA as well as single and/or doublestranded DNA.
- Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule.
- a nucleic acid molecule may be a non-naturally occurring molecule, e.g.
- nucleic acid, ”“DNA, ”“RNA,” and/or similar terms include nucleic acid analogs, e.g. analogs having other than a phosphodiester backbone. Nucleic acids may be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g.
- nucleic acids may comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications.
- a nucleic acid sequence is presented in the 5' to 3' direction unless otherwise indicated.
- a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g.
- methylated bases methylated bases
- intercalated bases modified sugars (e.g. 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g. phosphorothioates and 5'-N-phosphoramidite linkages).
- modified sugars e.g. 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose
- modified phosphate groups e.g. phosphorothioates and 5'-N-phosphoramidite linkages
- backbone refers to the component of the guide RNA that comprises the core region, also known as the crRNA/tracrRNA.
- the backbone is separate from the guide sequence, or spacer, region of the guide RNA, which has complementarity to a protospacer of a nucleic acid molecule.
- nucleic acid programmable DNA binding protein refers to any protein that may associate (e.g., form a complex) with one or more nucleic acid molecules (i.e. , which may broadly be referred to as a “napDNAbp-programming nucleic acid molecule” and includes, for example, guide RNA in the case of Cas systems) which direct or otherwise program the protein to localize to a specific target nucleotide sequence (e.g., a gene locus of a genome) that is complementary to the one or more nucleic acid molecules (or a portion or region thereof) associated with the protein, thereby causing the protein to bind to the nucleotide sequence at the specific target site.
- a specific target nucleotide sequence e.g., a gene locus of a genome
- napDNAbp embraces CRISPR-Cas9 proteins, as well as Cas9 equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or modified), and may include a Cas9 equivalent from any type of CRISPR system (e.g., type II, V, VI), including Casl2a (a type-V CRISPR-Cas system) (formerly known as Cpfl), C2cl (a type V CRISPR-Cas system), C2c2 (a type VI CRISPR-Cas system), C2c3 (a type V CRISPR-Cas system), a GeoCas9, a CjCas9, a Cas 12b, a Casl2g, a Casl2h, a Casl2i, a Casl3b, a Casl3c, a Casl3d, a Casl4, a Csn2, an x
- the napDNAbp may be a Cas9 domain that comprises a nuclease active Cas9 domain, a nuclease inactive Cas9 (dCas9) domain, or a Cas9 nickase (nCas9) domain.
- Cas equivalents are described in Makarova et al.,“C2c2 is a singlecomponent programmable RNA-guided RNA-targeting CRISPR effector,” Science 2016; 353 (6299), the contents of which are incorporated herein by reference.
- the nucleic acid programmable DNA binding protein (napDNAbp) that may be used in connection with this disclosure are not limited to CRISPR-Cas systems.
- the claimed invention embraces any such programmable protein, such as the Argonaute protein from Natronobacterium gregoryi (NgAgo) which may also be used for DNA-guided genome editing.
- NgAgo-guide DNA system does not require a PAM sequence or guide RNA molecules, which means genome editing can be performed simply by the expression of generic NgAgo protein and introduction of synthetic oligonucleotides on any genomic sequence. See Gao et al, DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nature Biotechnology 2016; 34(7):768-73, which is incorporated herein by reference.
- the napDNAbp is a RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex.
- the bound RNA(s) is referred to as a guide RNA (gRNA).
- gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule.
- gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though “gRNA” is used interchangeabley to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules.
- gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid (e.g., and directs binding of a Cas9 (or equivalent) complex to the target); and (2) a domain that binds a Cas9 protein.
- domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure.
- domain (2) is homologous to a tracrRNA as depicted in Figure IE of Jinek et al, Science 337:816-821 (2012), the entire contents of which is incorporated herein by reference.
- gRNAs e.g., those including domain 2
- a gRNA comprises two or more of domains (1) and (2), and may be referred to as an “extended gRNA.”
- an extended gRNA will, e.g., bind two or more Cas9 proteins and bind a target nucleic acid at two or more distinct regions, as described herein.
- the gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site, providing the sequence specificity of the nuclease:RNA complex.
- the RNA- programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example Cas9 (Csnl) from Streptococcus pyogenes (see, e.g..“Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti J. J. et al.., Proc. Natl. Acad. Sci. U.S.A.
- the napDNAbp nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, these proteins are able to be targeted, in principle, to any sequence specified by the guide RNA.
- Methods of using napDNAbp nucleases, such as Cas9, for site-specific cleavage (e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA- guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W.Y. et al.
- napDNAbp -programming nucleic acid molecule or equivalently “guide sequence” refers the one or more nucleic acid molecules which associate with and direct or otherwise program a napDNAbp protein to localize to a specific target nucleotide sequence (e.g., a gene locus of a genome) that is complementary to the one or more nucleic acid molecules (or a portion or region thereof) associated with the protein, thereby causing the napDNAbp protein to bind to the nucleotide sequence at the specific target site.
- a specific target nucleotide sequence e.g., a gene locus of a genome
- a non limiting example is a guide RNA of a Cas protein of a CRISPR-Cas genome editing system.
- promoter refers to a nucleic acid molecule with a sequence recognized by the cellular transcription machinery and able to initiate transcription of a downstream gene.
- a promoter may be constitutively active, meaning that the promoter is always active in a given cellular context, or conditionally active, meaning that the promoter is only active in the presence of a specific condition.
- conditional promoter may only be active in the presence of a specific protein that connects a protein associated with a regulatory element in the promoter to the basic transcriptional machinery, or only in the absence of an inhibitory molecule.
- a subclass of conditionally active promoters are inducible promoters that require the presence of a small molecule “inducer” for activity.
- inducible promoters include, but are not limited to, arabinose-inducible promoters, Tet-on promoters, and tamoxifen-inducible promoters.
- inducible promoters include, but are not limited to, arabinose-inducible promoters, Tet-on promoters, and tamoxifen-inducible promoters.
- constitutive, conditional, and inducible promoters are well known to the skilled artisan, and the skilled artisan will be able to ascertain a variety of such promoters useful in carrying out the present disclosure, which is not limited in this respect.
- the disclosure provides vectors with appropriate promoters for driving expression of the nucleic acid sequences encoding the fusion proteins (or one or more individual components thereof).
- recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.
- the term “subject,” as used herein, refers to an individual organism, for example, an individual mammal.
- the subject is a human.
- the subject is a non-human mammal.
- the subject is a non-human primate.
- the subject is a rodent.
- the subject is a sheep, a goat, a cattle, a cat, or a dog.
- the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode.
- the subject is a research animal.
- the subject is genetically engineered, e.g.
- target site refers to a sequence within a nucleic acid molecule that is edited by a fusion protein (e.g. a dCas9-deaminase fusion protein provided herein).
- the target site further refers to the sequence within a nucleic acid molecule to which a complex of the fusion protein and gRNA binds.
- treatment refers to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease, disorder, or condition, or one or more symptoms thereof, as described herein.
- treatment refers to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease, disorder, or condition, or one or more symptoms thereof, as described herein.
- treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g.
- treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g. in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their prevention or recurrence.
- variant refers to a protein having characteristics that deviate from what occurs in nature that retains at least one functional i.e. binding, interaction, or enzymatic ability and/or therapeutic property thereof.
- a “variant” is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the wild type protein.
- a variant of Cas9 may comprise a Cas9 that has one or more changes in amino acid residues as compared to a wild type Cas9 amino acid sequence.
- a variant of a deaminase may comprise a deaminase that has one or more changes in amino acid residues as compared to a wild type deaminase amino acid sequence, e.g. following ancestral sequence reconstruction of the deaminase.
- changes include chemical modifications, including substitutions of different amino acid residues truncations, covalent additions (e.g. of a tag), and any other mutations.
- This term also embraces fragments of a wild type protein.
- the level or degree of which the property is retained may be reduced relative to the wild type protein but is typically the same or similar in kind. Generally, variants are overall very similar, and in many regions, identical to the amino acid sequence of the protein described herein. A skilled artisan will appreciate how to make and use variants that maintain all, or at least some, of a functional ability or property.
- the variant proteins may comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%, identical to, for example, the amino acid sequence of a wild-type protein, or any protein provided herein (e.g. Cas9 protein, fusion protein, and fusion protein protein).
- Further polypeptides provided in the disclosure are encoded by polynucleotides which hybridize to the complement of a nucleic acid molecule encoding a protein such as a Cas9 protein under stringent hybridization conditions (e.g. hybridization to filter bound DNA in 6x Sodium chloride/Sodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in 0.2. times.
- stringent hybridization conditions e.g. hybridization to filter bound DNA in 6x Sodium chloride/Sodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in 0.2. times.
- SSC 0.1 % SDS at about 50-65 degrees Celsius
- highly stringent conditions e.g. hybridization to filter bound DNA in 6x sodium chloride/S odium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in O.IxSSC, 0.2% SDS at about 68 degrees Celsius
- other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F. M. et al, eds., 1989 Current Protocol in Molecular Biology , Green publishing associates, Inc., and John Wiley & Sons Inc., New York, at pp. 6.3.1-6.3.6 and 2.10.3).
- polypeptide having an amino acid sequence at least, for example, 95% “identical” to a query amino acid sequence it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
- the amino acid sequence of the subject polypeptide may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
- up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, or substituted with another amino acid.
- These alterations of the reference sequence may occur at the amino- or carboxy-terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to, for instance, the amino acid sequence of a protein such as a Cas9 protein, can be determined conventionally using known computer programs.
- a preferred method for determining the best overall match between a query sequence (a sequence of the present disclosure) and a subject sequence can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)).
- the query and subject sequences are either both nucleotide sequences or both amino acid sequences.
- the result of said global sequence alignment is expressed as percent identity.
- the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.
- the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C- terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score.
- This final percent identity score is what is used for the purposes of the present disclosure. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.
- wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
- CTD1 and CTD2 mouse alleles were intended to model the two most common RTT CTD patient mutations, (a) Male mice hemizygous for the CTD1 mutation show the expected RTT- like phenotypes, similar to Mecp2 null animals, whereas CTD2 mice appear indistinguishable from wild-type littermates, (b) CTD1 mice show reduced survival (median age at death 20 weeks).
- CTD2 mice have 100% survival at one year, as WT littermates, (c) CTD2 mice express truncated MeCP2 at WT levels (whole brain protein from 6 week-old mice), whereas CTD1 mice have reduced levels of MeCP2 protein in brain, (d) Due to differences in amino acid sequence between mouse and humans, the mouse CTD2 allele encodes -SPX at the C- terminus rather than -PPX found in patients with the equivalent mutation. Both mouse and patient alleles for CTD1 end with -PPX;
- the human MECP2 deletion-prone region is shown with neutral variants from the ExAC and GnomAD databases: in-frame deletion variants are shown above and missense mutations below. Green lines indicate deleted nucleotides. Letters below indicated missense amino acid changes, with those found in more than 10 individuals indicated in purple and more than 50 individuals in bold purple. Numbering of the DNA and amino acid sequence is that of the E2 isoform;
- the human MECP2 commonly deleted region is shown with the possible amino acid sequences arising from frameshifting deletions.
- the C-terminal amino acid sequences of MeCP2 from Rett mutations and neutral variants with C-terminal deletions are shown, with the frameshifted amino acids using bold or italic typeface according to their frame.
- STOP codons X are underlined;
- CTD1 NS knock-in mouse replaces the TGA stop by a TGG tryptophan codon
- (d) Male mice hemizygous for the CTD1 mutation show RTT-like phenotypes similar to Mecp2 null animals, while CTD1 NS mice are indistinguishable from wild-type littermates;
- FIG. 6 A cell culture system to test base editing reagents
- FIG. 7 A to G editing in cultured human cells expressing a MeCP2 CTD1 transgene
- Nucleotide sequence of the region surrounding the target adenine (A) in the CTD1 Mecp2 transgene The target A is indicated as position 0 and bystander As within the guide RNA sequence as 6 and 9.
- Guide RNA sequences are shown below, with their optimal editing windows indicated by a bar.
- Guides 1 and 2 can be utilized bySpG and SpRY ABE8es, and guide 5 by SpRY ABE8e only,
- ExAC and GnomAD sequencing databases (comprising exome and genomic sequence data from individuals in the general population, known not to suffer with severe neurological disease) were searched for deletions in the C-terminal region of MECP2. These deletions (see Figure 2) are depicted above the nucleotide and amino acid sequence of the region.
- the information was extracted from ExAC and GnomAD v 2.1.1 and v3 in October 2019 and from GnomAD in May 2023, when 3 additional frameshifting deletions were found GnomAD v3, namely 1167del7, 1167del34 and 1183del4.
- the three possible reading frames of the C-terminal deletion-prone region are shown in Figure 4: the normal reading frame in standard type, +1 in italic and +2 in bold.
- Below the C-terminal amino acid sequence of the frame-shifting deletions in Figure 2 are shown.
- the correct amino acids before the frame-shift are shown in standard type, with those after formatted according to the frame, which is shifted to. It is apparent that the pathogenic mutations shift to the +2 frame, whilst the neutral variants shift to the +1 frame. It can be seen that the c-terminal amino acid sequence -PPX is common to all the RTT mutations.
- a knock-in mouse allele was produced in mouse ES cells.
- WT JLI09 ES cells were transfected with SpCas9 plasmid pX330 with guide sequence GACCTGAGCCTGAGAGCTCTG cloned into the Bbsl site.
- the initial G of the guide sequence is not present in the genomic sequence and was added to aid transcription of the guide using the U6 promoter.
- the A to G change from the sequence found in the CTD1 mouse is in bold and underlined.
- ES cell clones were screened for the correct modification of the Mecp2 gene and a correctly targeted clone was used to generate a mouse line by injection into mouse blastocysts. The resultant chimeric founders were bred to establish the CTD1 NS line.
- the level of MeCP2 protein in the brains of CTD1 NS hemizygous male mice was measured by western blotting of whole brain extracts Figure 5(b) (method as described in Guy et al, 2018).
- the CTD1 NS MeCP2 protein was slightly larger than CTD1 , as expected due to the extended tail of missense amino acids, and expressed at levels at or above those in WT littermates (quantified in Figure 5(c)).
- CTD1 NS hemizygous males did not show the RTT-like phenotypes seen in the CTD1 line (and other RTT mouse models) and were indistinguishable from WT littermates when scored weekly Figure 5(d) as previously described (Guy et al, 2018 and references therein). All CTD1 NS animals survived to one year (CTD1 male hemizygotes median survival 20 weeks).
- This mouse model shows that changing the stop codon in a CTD allele to tryptophan using, for example, adenine base editing is likely to prove therapeutic for this class of patients.
- a cell line model system was used to test ABE plasmids and guide RNA sequences for adenine editing efficiency.
- Cell lines with tetracycline-inducible Mecp2 cDNA transgenes Figure 6(a) were created using the Flp-lnTM T-RexTM system (ThermoFisher).
- WT and mutant Mecp2 cDNAs (mouse e1 isoform) were cloned into vector pcDNA5/FRT/TO and the resulting plasmids were transfected into Flp-lnTM T-RexTM 293 cell line along with the Flp plasmid pOG44.
- Cells are transfected with ABE and Guide constructs using Lipofectamine 2000 transfection reagent. After 24 hours the transfection medium is replaced with standard growth medium and cells are then grown for a further 4-5 days before harvesting cell pellets for further analysis by trypsination. For protein or mRNA analysis cells are induced with tetracycline (typically 0.5 ,g/ml) for 3-24 hours. It should be noted that there was no selection for transfected cells in these experiments, although the transfection efficiency, as estimated by expression of a GFP marker from the ABE plasmids, was high at around 80%. The editing efficiencies are therefore lower than they would be if only transfected cells were considered. Figure 7 shows results from a typical transfection experiment to determine the editing efficiency of different ABE/guideRNA combinations.
- ABE constructs tested were fusions SpG-ABE8 and SpRY-ABE8, formed between a deaminase and nCas9 domain. These constructs consist of adenine deaminase domains as described in Richter et a (2020) (ABE8e) combined with the nCas9 SpG and SpRY variants described in Walton et al (2020). Methods of making fusions are described by Kluesner et al. (2021); Nishida, K. et al. (2016); Komor, A. C., 2016 and Gaudeili N. M. et al. (2017).
- SpG guide 1 CCCCTGAGCCTCAGGACTTG (AGC), A to be edited at guide position 7
- SpG guide 2 CTGAGCCTCAGGACTTGAGC (AGC), A to be edited at guide position 4
- SpRY guide 5 CCTGAGCCTCAGGACTTGAG (CAG),A to be edited at guide position 5
- Guides 1 and 2 can be used by SpG- and SpRY-ABE8e due to their NGN PAM sequence (shown in brackets after the guide sequence).
- Guide 5 can only be used with SpRY-ABE8e due to the NAN PAM.
- the pGuide plasmid with no guide sequence inserted was used in combination with an ABE. This was termed “empty guide” or “gO”.
- genomic DNA analysis the region surrounding the edited base was amplified by PCR and either the bulk PCR was Sanger sequenced, or amplicons were used for high-throughput sequencing using the Illumina Mi-Seq platform.
- sequencing traces were analysed using webtool EditR (Kluesner et al, 2018).
- Protein levels after editing were measured using western blotting of protein extracts from cell pellets harvested after tetracycline induction Figures 7(c), (d). Total intensity of the CTD1 MeCP2 bands (edited and unedited) in each lane was normalised to the histone H3 loading control band. These values were then further normalised with the mean value of the empty guide samples set as 1 , Figure 7(d). Each lane/value represents an independently transfected well of cells.
- Figure 7 (b) - (d) show all combinations of ABE8e and guide plasmids.
- Five days after transfection cells were induced with tetracycline for 4 hours and then each dish was trypsinised, the cells split into three aliquots and pelleted cells snap frozen and used to prepare genomic DNA, protein or total RNA. Each data point represents an independently transfected dish of cells.
- guides 2 and 5 also had significant A to G editing at bystander positions 6 and 9 within the guide sequence. Although these edits do not affect the amino acid sequence of the CTD1 allele as here they are silent mutations, they would make missense edits on the WT allele.
- ABE8e construct into two parts in order to fit them into two AAV vectors ( Figure 8).
- the use of split intein sequences in the constructs means that the two halves are joined by protein splicing when they are expressed in the same cell, to produce functional full-length protein.
- AAV is the vector of choice for delivery to brain (initially in mice in our case), but has a size limit less than a single ABE expression construct.
- the use of two AAV vectors and splitting a nucleic acid into two parts, as achieved above, is described, for example, in Chen (2020). Pairs of split constructs made from both SpG and SpRY ABE8e were tested in combination with SpG guide 1 and compared with the equivalent full-length ABE8es.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions destinées à être utilisées dans le traitement d'une classe de mutations du syndrome de Rett, à savoir des délétions C-terminales, comprenant un éditeur de base pour modifier un codon d'arrêt dans un gène MECP2 mutant. Cette modification ne renvoie pas le gène à sa forme de type sauvage (WT), mais rétablit des niveaux normaux d'une version qui est fonctionnellement équivalente à une version de type sauvage de la protéine MeCP2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263375008P | 2022-09-08 | 2022-09-08 | |
US63/375,008 | 2022-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024052681A1 true WO2024052681A1 (fr) | 2024-03-14 |
Family
ID=88295935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2023/052315 WO2024052681A1 (fr) | 2022-09-08 | 2023-09-07 | Traitement du syndrome de rett |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024052681A1 (fr) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035136A2 (fr) | 2013-09-06 | 2015-03-12 | President And Fellows Of Harvard College | Système d'administration pour des nucléases fonctionnelles |
US20150166980A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Fusions of cas9 domains and nucleic acid-editing domains |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
WO2017070632A2 (fr) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Éditeurs de nucléobases et leurs utilisations |
WO2018027078A1 (fr) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Éditeurs de nucléobases d'adénosine et utilisations associées |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2018176009A1 (fr) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Éditeurs de nucléobase comprenant des protéines de liaison à l'adn programmable par acides nucléiques |
WO2019023680A1 (fr) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace) |
WO2019079347A1 (fr) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Utilisations d'éditeurs de bases adénosine |
WO2019217944A1 (fr) * | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Procédés d'édition de polymorphisme mononucléotidique à l'aide de systèmes d'éditeur de bases programmables |
WO2019226593A1 (fr) | 2018-05-24 | 2019-11-28 | Aqua-Aerobic Systems, Inc. | Système et procédé de traitement de matières solides dans un système de filtration |
WO2020051360A1 (fr) | 2018-09-05 | 2020-03-12 | The Broad Institute, Inc. | Édition de base pour le traitement du syndrome de hutchinson-gilford, progeria |
WO2020086908A1 (fr) | 2018-10-24 | 2020-04-30 | The Broad Institute, Inc. | Constructions pour édition génomique dépendante de la hdr améliorée |
WO2020102659A1 (fr) | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | Éditeurs de base de g en t et leurs utilisations |
WO2020168051A1 (fr) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Procédés d'édition d'un gène associé à une maladie à l'aide d'éditeurs de bases d'adénosine désaminase, y compris pour le traitement d'une maladie génétique |
WO2020214842A1 (fr) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Éditeurs de base d'adénine présentant des effets hors cible réduits |
WO2020236936A1 (fr) * | 2019-05-21 | 2020-11-26 | Beam Therapeutics Inc. | Procédés d'édition d'un polymorphisme mononucléotidique au moyen de systèmes d'éditeur de base programmables |
-
2023
- 2023-09-07 WO PCT/GB2023/052315 patent/WO2024052681A1/fr unknown
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035136A2 (fr) | 2013-09-06 | 2015-03-12 | President And Fellows Of Harvard College | Système d'administration pour des nucléases fonctionnelles |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US20150166980A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Fusions of cas9 domains and nucleic acid-editing domains |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2017070632A2 (fr) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Éditeurs de nucléobases et leurs utilisations |
WO2017070633A2 (fr) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Protéines cas9 évoluées pour l'édition génétique |
US20170121693A1 (en) | 2015-10-23 | 2017-05-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2018027078A1 (fr) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Éditeurs de nucléobases d'adénosine et utilisations associées |
US20180073012A1 (en) | 2016-08-03 | 2018-03-15 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018176009A1 (fr) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Éditeurs de nucléobase comprenant des protéines de liaison à l'adn programmable par acides nucléiques |
WO2019023680A1 (fr) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace) |
WO2019079347A1 (fr) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Utilisations d'éditeurs de bases adénosine |
WO2019217944A1 (fr) * | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Procédés d'édition de polymorphisme mononucléotidique à l'aide de systèmes d'éditeur de bases programmables |
WO2019226593A1 (fr) | 2018-05-24 | 2019-11-28 | Aqua-Aerobic Systems, Inc. | Système et procédé de traitement de matières solides dans un système de filtration |
WO2020051360A1 (fr) | 2018-09-05 | 2020-03-12 | The Broad Institute, Inc. | Édition de base pour le traitement du syndrome de hutchinson-gilford, progeria |
WO2020086908A1 (fr) | 2018-10-24 | 2020-04-30 | The Broad Institute, Inc. | Constructions pour édition génomique dépendante de la hdr améliorée |
WO2020102659A1 (fr) | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | Éditeurs de base de g en t et leurs utilisations |
WO2020168051A1 (fr) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Procédés d'édition d'un gène associé à une maladie à l'aide d'éditeurs de bases d'adénosine désaminase, y compris pour le traitement d'une maladie génétique |
WO2020214842A1 (fr) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Éditeurs de base d'adénine présentant des effets hors cible réduits |
WO2020236936A1 (fr) * | 2019-05-21 | 2020-11-26 | Beam Therapeutics Inc. | Procédés d'édition d'un polymorphisme mononucléotidique au moyen de systèmes d'éditeur de base programmables |
Non-Patent Citations (45)
Title |
---|
"Current Protocol in Molecular Biology", 1989, GREEN PUBLISHING ASSOCIATES, INC., AND JOHN WILEY & SONS INC. |
BEBBINGTON ET AL., JOURNAL OF MEDICAL GENETICS, vol. 47, 2010, pages 242 - 248 |
BRUTLAG ET AL., COMP. APP. BIOSCI., vol. 6, 1990, pages 237 - 245 |
CHEN ET AL., BIORXIV (DOI: HTTPS://DOI.ORG/10.1101/2022.08.12.503700), 2022 |
CHEN ET AL., SMALL METHODS, vol. 4, 2020 |
CONG, L. ET AL.: "Multiplex genome engineering using CRISPR/Cas systems", SCIENCE, vol. 339, 2013, pages 819 - 823, XP055400719, DOI: 10.1126/science.1231143 |
COOREY BRONTE ET AL: "Gene Editing and Rett Syndrome: Does It Make the Cut?", THE CRISPR JOURNAL, vol. 5, no. 4, 12 August 2022 (2022-08-12), pages 490 - 499, XP093107968, ISSN: 2573-1599, Retrieved from the Internet <URL:https://dx.doi.org/10.1089/crispr.2022.0020> DOI: 10.1089/crispr.2022.0020 * |
DELTCHEVA E. ET AL.: "CRISPR RNA maturation by trans- encoded small RNA and host factor RNase III", NATURE, vol. 471, 2011, pages 602 - 607, XP055619637, DOI: 10.1038/nature09886 |
DELTCHEVA E. ET AL.: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, 2011, pages 602 - 607, XP055619637, DOI: 10.1038/nature09886 |
DICARLO, J. E. ET AL.: "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems", NUCLEIC ACID RES., 2013 |
ERDAKI, A. ET AL., MOL. CELL, vol. 73, 2019, pages 714 - 726 |
FERRETTI J.J. ET AL.: "Complete genome sequence of an MI strain of Streptococcus pyogenes", PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 4658 - 4663, XP002344854, DOI: 10.1073/pnas.071559398 |
GAO ET AL.: "DNA-guided genome editing using the Natronobacterium gregoryi Argonaute", NATURE BIOTECHNOLOGY, vol. 34, no. 7, 2016, pages 768 - 73, XP055518128, DOI: 10.1038/nbt.3547 |
GAUDELLI ET AL., NATURE BIOTECHNOLOGY, vol. 38, 2020, pages 883 - 891 |
GAUDELLI NICOLE M ET AL: "Directed evolution of adenine base editors with increased activity and therapeutic application", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 7, 13 April 2020 (2020-04-13), pages 892 - 900, XP037187542, ISSN: 1087-0156, [retrieved on 20200413], DOI: 10.1038/S41587-020-0491-6 * |
GAUDELLI, N. M. ET AL., NATURE, vol. 551, 2017, pages 464 - 471 |
GREENSAMBROOK: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS |
GRIMM NIKLAS-BENEDIKT ET AL: "Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 38, no. 9, 2 March 2022 (2022-03-02), pages 920 - 943, XP087143386, ISSN: 0168-9525, [retrieved on 20220302], DOI: 10.1016/J.TIG.2022.01.007 * |
GRUNEWALD ET AL., NAT BIOTECHNOL, vol. 37, 2019, pages 1041 - 1048 |
GUY ET AL., HUM. MOL. GENET., 2018 |
GUY JACKY ET AL: "A mutation-led search for novel functional domains in MeCP2", HUMAN MOLECULAR GENETICS, vol. 27, no. 14, 27 April 2018 (2018-04-27), GB, pages 2531 - 2545, XP093107964, ISSN: 0964-6906, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030874/pdf/ddy159.pdf> DOI: 10.1093/hmg/ddy159 * |
HWANG, W.Y. ET AL.: "Efficient genome editing in zebrafish using a CRISPR-Cas system", NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 227 - 229, XP055086625, DOI: 10.1038/nbt.2501 |
JIANG, W. ET AL.: "RNA-guided editing of bacterial genomes using CRISPR-Cas systems", NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 233 - 239, XP055249123, DOI: 10.1038/nbt.2508 |
JINEK M. ET AL.: "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, vol. 337, 2012, pages 816 - 821, XP055229606, DOI: 10.1126/science.1225829 |
JINEK, M. ET AL.: "RNA-programmed genome editing in human cells", ELIFE, vol. 2, 2013, pages e00471, XP002699851, DOI: 10.7554/eLife.00471 |
JOHN R. SINNAMON ET AL: "Site-directed RNA repair of endogenous Mecp2 RNA in neurons", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 44, 16 October 2017 (2017-10-16), pages E9395 - E9402, XP055588475, ISSN: 0027-8424, DOI: 10.1073/pnas.1715320114 * |
KARCZEWSKI ET AL., NATURE, vol. 581, 2020, pages 434 - 443 |
KLEINSTIVER, B. P. ET AL., NATURE, vol. 533, 2016, pages 420 - 424 |
KLUESNER ET AL., NATURE COMMUNICATIONS, vol. 12, no. 2437, 2021 |
KOMOR, A.C. ET AL.: "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", NATURE, vol. 533, 2016, pages 420 - 424, XP093078921, DOI: 10.1038/nature17946 |
KRISHNARAJ ET AL., HUMAN MUTATION, vol. 38, 2017 |
MAKAROVA ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 2016, XP055407082, DOI: 10.1126/science.aaf5573 |
MALI, P. ET AL.: "RNA-guided human genome engineering via Cas9", SCIENCE, vol. 339, 2013, pages 823 - 826, XP055469277, DOI: 10.1126/science.1232033 |
MERRITT JONATHAN K ET AL: "Pharmacological read-through of R294X Mecp2 in a novel mouse model of Rett syndrome", HUMAN MOLECULAR GENETICS, vol. 29, no. 15, 29 May 2020 (2020-05-29), GB, pages 2461 - 2470, XP093107973, ISSN: 0964-6906, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471501/pdf/ddaa102.pdf> DOI: 10.1093/hmg/ddaa102 * |
NAT. REV. GENET., vol. 19, no. 12, 2018, pages 770 - 788 |
NISHIDA, K. ET AL., SCIENCE, vol. 16, no. 6305, 2016, pages 353 |
QI ET AL., CELL, vol. 152, no. 5, 2013, pages 1173 - 83 |
REES ET AL., SCIENCE ADVANCESM, vol. 5, 2019 |
ROSS ET AL., HUMAN MOLECULAR GENETICS, vol. 25, 15 October 2016 (2016-10-15), pages 4389 - 4404 |
SINNAMON JOHN R. ET AL: "In Vivo Repair of a Protein Underlying a Neurological Disorder by Programmable RNA Editing", CELL REPORTS, vol. 32, no. 2, 14 July 2020 (2020-07-14), US, pages 107878, XP055962460, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2020.107878 * |
SLAYMAKER ET AL., SCIENCE, vol. 351, 2015, pages 84 - 88 |
VAKULSKAS ET AL., NATURE MEDICINE, vol. 24, 2018, pages 1216 - 1224 |
VASHI NEETI ET AL: "Treating Rett syndrome: from mouse models to human therapies", MAMMALIAN GENOME, SPRINGER NEW YORK LLC, US, vol. 30, no. 5, 28 February 2019 (2019-02-28), pages 90 - 110, XP036824827, ISSN: 0938-8990, [retrieved on 20190228], DOI: 10.1007/S00335-019-09793-5 * |
WALTON ET AL., SCIENCE, vol. 368, 2020, pages 290 - 296 |
ZHANG HAN ET AL: "Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector", GEN BIOTECHNOLOGY, vol. 1, no. 3, 14 June 2022 (2022-06-14), pages 285 - 299, XP093069319, ISSN: 2768-1572, DOI: 10.1089/genbio.2022.0015 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7383062B2 (ja) | 配列操作のための最適化されたCRISPR-Cas二重ニッカーゼ系、方法および組成物 | |
JP7201153B2 (ja) | プログラム可能cas9-リコンビナーゼ融合タンパク質およびその使用 | |
US11319532B2 (en) | High efficiency base editors comprising Gam | |
JP6625971B2 (ja) | 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化 | |
US20240173430A1 (en) | Base editing for treating hutchinson-gilford progeria syndrome | |
US20220177877A1 (en) | Highly multiplexed base editing | |
DE112020001339T5 (de) | Verfahren und zusammensetzung zum editing von nukleotidsequenzen | |
CN114072496A (zh) | 腺苷脱氨酶碱基编辑器及使用其修饰靶标序列中的核碱基的方法 | |
EP3790963A1 (fr) | Procédés d'édition de polymorphisme mononucléotidique à l'aide de systèmes d'éditeur de bases programmables | |
WO2021050571A1 (fr) | Nouveaux éditeurs de nucléobases et leurs procédés d'utilisation | |
CN114072509A (zh) | 脱氨反应脱靶减低的核碱基编辑器和使用其修饰核碱基靶序列的方法 | |
JP2022500017A (ja) | 核酸塩基編集システムを送達するための組成物および方法 | |
CN114096666A (zh) | 治疗血红素病变的组合物和方法 | |
WO2020168075A1 (fr) | Rupture de site accepteur d'épissage d'un gène associé à une maladie à l'aide d'éditeurs de bases d'adénosine désaminase, y compris pour le traitement d'une maladie génétique | |
EP3923994A1 (fr) | Compositions et méthodes de traitement de déficience en alpha-1 antitrypsine | |
CN114026237A (zh) | 用于治疗1a型糖原贮积病的组成物和方法 | |
JP2024501892A (ja) | 新規の核酸誘導型ヌクレアーゼ | |
EP4263825A1 (fr) | Virus de la rage recombinants pour thérapie génique | |
WO2024052681A1 (fr) | Traitement du syndrome de rett | |
WO2023086953A1 (fr) | Compositions et procédés pour le traitement de l'œdème de quincke héréditaire (hae) | |
Duan et al. | Engineering essential genes with a | |
AU2022343725A1 (en) | Viral guide rna delivery | |
CN116685684A (zh) | 用于治疗1a型糖原贮积症的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23786121 Country of ref document: EP Kind code of ref document: A1 |